A large retrospective study published today analyzed over 100,000 women and observed that those on GLP-1s were up to 35% less likely to develop breast cancer. Experts say the link may be driven by ...

The strongest signals were seen in epigenetic measures linked to inflammation, brain, heart, blood, kidney, liver and ...

Ozempic-style drugs have been flagged as possible treatments for cancer, dementia, endo, addiction and more. An expert ...

Millions of Americans are currently taking GLP-1 medications such as Ozempic or Wegovy for weight loss. But along with the fat, many are quietly losing something else: muscle. Unlike fat, muscle doesn ...

But a new mouse study suggests part of its hunger-suppressing power comes from the hindbrain — an evolutionarily old region at the base of the brain that helps regulate basic survival functions, ...

Ozempic was supposed to be a gut story. Then Allison Shapiro looked at the brain scans. An assistant professor at the ...

Ozempic and Wegovy, both produced by Novo Nordisk, currently cost hundreds of dollars a month, depending on the dosage ...

New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone.

Learn about retatrutide, a new weight-loss drug that works differently than other GLP-1s and helped patients in a clinical ...

Eli Lilly on Thursday released results from TRIUMPH-1, its pivotal Phase 3 trial for the experimental obesity drug ...

Ageing populations could create an explosion in healthcare costs for society. But with new treatments, there are ...

A team of researchers at the National Institutes of Health (NIH) have unveiled new details about the events GLP-1 receptor agonists trigger within ...